Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 413

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Cardiovascular Side Effects of Cancer Therapies: A Position Statement from the Heart Failure Association of the European Society of Cardiology

Eschenhagen, Thomas, Force, Thomas, Ewer, Michael S., de Keulenaer, Gilles W., Suter, Thomas M., Anker, Stefan D., Avkiran, Metin, de Azambuja, Evandro, Balligand, Jean-Luc, Brutsaert, Dirk L., Condorelli, Gianluigi, Hansen, Arne, Heymans, Stephane, Hill, Joseph A., Hirsch, Emilio, Hilfiker-Kleiner, Denise, Janssens, Stefan, de Jong, Steven, Neubauer, Gitte, Pieske, Burkert, Ponikowski, Piotr, Pirmohamed, Munir, Rauchhaus, Mathias, Sawyer, Douglas, Sugden, Peter H., Wojta, Johann, Zannad, Faiez, Shah, Ajay M.·2011·European Journal of Heart Failure

Abstract

The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfq213

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 413

Metadata

Authors
Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., Condorelli, G., Hansen, A., Heymans, S., Hill, J. A., Hirsch, E., Hilfiker-Kleiner, D., Janssens, S., de Jong, S., Neubauer, G., Pieske, B., Ponikowski, P., Pirmohamed, M., Rauchhaus, M., Sawyer, D., Sugden, P. H., Wojta, J., Zannad, F., & Shah, A. M.
Venue
European Journal of Heart Failure
Published
2011-01-01
Volume
13
Issue
1
Pages
1-10
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2098268167
Cited by
413
References
5
FWCI
14.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular Side Effects of Cancer Therapies: A Position Statement from the Heart Failure Association of the European Society of Cardiology. https://app.cochat.ai/papers/10.1093/eurjhf/hfq213
The paper
Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., Condorelli, G., Hansen, A., Heymans, S., Hill, J. A., Hirsch, E., Hilfiker-Kleiner, D., Janssens, S., de Jong, S., Neubauer, G., . . . Shah, A. M. (2011). Cardiovascular Side Effects of Cancer Therapies: A Position Statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfq213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.